Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Trial details
- Registry ID
- NCT07007312
- Drugs studied
- Azacitidine (AZA), Cytarabine (Ara-C), Daunorubicin, Venetoclax and 1 more
TrialRedline tracks 6 clinical trials sponsored by Kura Oncology, Inc.: 1 Phase 3, 5 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312 | Azacitidine (AZA), Cytarabine (Ara-C), Daunorubicin, Venetoclax and 1 more | Recruiting | 2031-11Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyNCT03719690 | HRAS Detection Assay, Tipifarnib | Completed | 2023-05-02Actual |
| Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyNCT02464228 | Tipifarnib | Completed | 2021-03-31Actual |
| Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsNCT02383927 | Tipifarnib | Completed | 2020-12-14Actual |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaNCT02807272 | Tipifarnib | Completed | 2020-11-30Actual |
| Tipifarnib in Subjects With Myelodysplastic SyndromesNCT02779777 | Tipifarnib | Terminated | 2018-08-28Actual |
Names as written in the registry records.